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The ability  of viruses to persist in  the circulation  and  in  tissues of man  and 
animals  for long  periods  of  time  is  now  well  established.  In  many  persistent 
infections,  viral  replication  continues  despite  the  production  of  circulating 
antibody(s)  directed  against  viral  antigens  (1-6).  Indeed,  the  major  tissue 
injuries  associated  with  such  persistent  viral  infections  are due  to  trapping  of 
virus-antiviral  antibody  (V-Ab) ~ immune complexes along filtering membranes 
in glomeruli, arteries,  and the choroid plexus with resulting glomerulonephritis, 
arteritis,  and choroiditis,  respectively (1, 2,  7). 
Studies carried out on several persistent viral infections suggest that comple- 
ment  binds  to  V-Ab  immune  complexes  in  vivo.  Evidence  that  virus  in  the 
serum  complexes  with  host  immunoglobulin  (Ig)  and  complement  (C)  comes 
from  experiments  in  which  specific  precipitation  of  either  Ig  or  C  from  the 
serum  removes significant  infectivity,  while  precipitation  of other  serum  pro- 
teins,  such as albumin,  removes none  (3, 5, 6, 8,  9). Examination  of glomeruli, 
arteries,  or choroid plexus shows a progressive accumulation  of Ig, C, and viral 
antigens  in irregular deposits along the  basement membrane of capillary walls 
(1, 2). In addition  to demonstrating  V-Ab-C immune complexes, these findings 
also indicate  a  failure  of the immune surveillance  mechanism  to eliminate  the 
infectious virus. 
In the present study, we have investigated the role of antibody and C, in both 
the formation of V-Ab-C complexes and in the neutralization  of polyoma virus. 
This virus is potentially oncogenic,  able to cause persistent  viral infection,  and 
has been associated with immune complex formation  (10).  We have found that 
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C  markedly enhances  the aggregation of V-Ab complexes, and  thereby plays a 
significant  role  in  neutralization  of  this  nonenveloped  DNA  virus.  This  is 
accomplished  by  C3-dependent  cross-linking  of  viral  particles  with  resulting 
reduction in the net number of infectious aggregates. This new action of C3 and 
the presence of C3b on the viral surface has important  implications for the fate 
of polyoma virus and perhaps  other viruses in vivo. 
Materials and Methods 
Purification and Titration of Virus.-- 
Polyoma virus:  Small plaque type polyoma virus passed through mouse kidneys was ob- 
tained from Dr.  R. Dulbecco, Salk Institute, La Jolla, Calif. Virus pools were made as de- 
scribed  by  Winocour  and  virus  was  purified  by  modification of Crawford's  method  (11). 
Briefly, kidneys were taken from 14-day old Ha/ICR or SWR/J mice infected 10 days earlier 
with 1 )<  10 e plaque-forming U  (PFU) of virus, minced, trypsinized, and placed in culture. 
When cytopathogenicity (CPE) was noted 6-8 days later, the supernate from the culture was 
collected, cleared of debris by low speed centrifugation (15 min at 700 g), and pelleted by ultra- 
centrifugation  (4 h  at 80,000  g in a Beckman L2-65 ultracentrifuge  [Beckman Instruments, 
Inc., Fullerton, Calif.]).  The pellet was suspended in 50 mM Tris-HC1 buffer, pH 8, sonicated, 
and sequentially banded twice by equilibrium density gradient centrifugafion in cesium chloride 
(24 h at 114,000 g). The lower band, which contains "full" polyoma particles, was collected and 
freed of cesium chloride by sedimenting the virus (4 h at 80,000 g). The pellet was resuspended 
in 50 mM Tris-HC1,  pH 8, containing 0.1~o bovine serum albumin and frozen at --70°C until 
use. The hemagglutinating ability of polyoma virus was determined with 0.6% guinea pig red 
blood cells and its plaque-forming ability by CPE for Ha/ICR or SWR/J mouse embryo fibro- 
blasts. An average preparation had 2-8  )<  106 hemagglufination U (HAU)/ml and a plaque- 
forming titer of 2-8 X  1011/ml.  The relationship between hemagglutinating U and  particles 
was used to calculate the number of virus particles present (11). The accuracy of this method 
was verified in preliminary experiments in which both virus particles were counted  (12) and 
hemagglutinating U determined. 
Preparation and Purification of Antiviral Antibodies. -Antibodies  to polyoma virus were 
made by injecting purified virus in incomplete Freund's adjuvant directly into popliteal lymph 
nodes of 3-4 kg rabbits. Rabbits were injected subcutaneously with virus in incomplete Freund's 
adjuvant every 28 days. Bleedings were done 7 days after each inoculation end antisera ob- 
tained were absorbed with noninfected tissue culture cells and  media. Hamster antibody  to 
polyoma virus was supplied by Dr. Kenneth Takemoto, NIAID, NIH, Bethesda, Md. Rabbit 
and hamster antibody to polyoma virus contained from 2-9 X  104 hemegglutination inhibition 
U/ml and at a dilution of 2 X  10  -3 the antibody inhibited 50% of polyoma virus PFU. Using 
125I-labeled polyome virus (see below) as an immunoabsorbant, we determined that 0.7% of 
131i_labele  d hamster IgG and 0.5% of 13 ii_labele  d rabbit IgG was antibody to polyoma virus. 
Antisera were heated at 56°C for 30 rain.  After initial fractionetion with saturated ammo- 
nium sulfate, the IgG fraction was obtained by chromatography on DEAE-cellulose columns, 
0.0175 M sodium phosphate, pH 7.4, for rabbit end 0.01 M, pH 8, for hamster, respectively. 
The effluent was collected, concentrated to 10 mg protein/ml, and shown to contain only IgG 
by immunoelectrophoresis and Ouchterlony analyses. 
Complement.--Individual guinea pig, rabbit, or human sera were used as a  C source.  For 
some studies,  C4-deficient guinea pig or C6-deficient rabbit sera were employed. Sera were 
collected, divided into small aliquots, and stored at --70°C until use. In those experiments in 
which the action of C was studied, sere were diluted in barbital saline with gelatin, calcium 
chloride, and magnesium chloride (13). 
C components C1, C2, C3, and C4 were isolated from human serum as reported  (14-17). 
Human C2 was used exclusively in the oxidized form (18). C component titrations were per- M.  B.  A.  OLDSTONE,  N.  R.  COOPER,  AND  D.  L.  LARSON  551 
formed after incubation of 50k of polyoma virus (usually containing 3-4 X  109 virus particles) 
with 50 #l of antipolyoma antibody and 100 #l of fresh serum for 50 min at 37°C. The method- 
ology employed has been published (19).  Controls without virus and without virus and anti- 
body were included and simultaneously titered. 
Labding  of Virus and Antibody.--To  label virus with  1~5I we used a  modification of the 
chloramine-T technique (20).  Briefly, 2-3 mCi of  1~5I and 5 #g of chloramine-T were added 
to 8-12 vg of purified virus (approximately 2  X  1011 full particles) suspended in 0.5 ml of 50 
mM Tris, pH 7.2, containing 0.1% bovine serum albumin (BSA), for 2 min at 4°C. The reac- 
tion was stopped by adding 5 ~g of sodium metabisulfite. After iodination, virus was diluted in 
C  buffer and centrifuged at 105,500  g for 2 h  to remove  nonviral-associated free iodine. The 
pellet was resuspended in 50 mM Tris, pH  7.2,  containing 0.1% BSA.  The  uptake  of  125I 
was 2-8%. 
The nucleic acid of polyoma virus was labeled with [3H] or [14C]thymidine and virus was 
purified as  previously  reported  (11).  Over 95%  of  [125I], [aH],  or  [14C]polyoma  virus was 
precipitable with TCA. 
To insure that 125i, 3  H or 14C labels were on the virion, a portion of radiolabeled virus was 
first incubated with specific rabbit or hamster antibody to polyoma virus for 30 min at 37°C 
and then with antibody to rabbit or hamster IgG, in excess,  for 30 min at 37°C.  The mixture 
was spun at 1,300 g for 20 min at 4°C, after which the supernate and precipitate were collected 
and analyzed for radioactivity. In other experiments labeled virus was rebanded either on a 
cesium chloride  (11)  or a  sucrose density gradient and  the relationship of virus density to 
radioactivity in the gradient was plotted. 
Formation and Centrifugation of V-Ab and  V-Ab-C  Complexes.--All  reagents were diluted 
in C buffer. Virus was incubated with antiviral antibody for 10 min at 37°C with gentle agita- 
tion in a water bath. In some experiments, fresh or heated (56°C for 30 min) guinea pig, rabbit, 
or human serum was added  to the V-Ab complex. In other experiments, highly purified in- 
dividual C components were added to the V-Ab complex. In the experiments in which comple- 
ment components were added to V-Ab mixtures, an attempt was made to duplicate the pre- 
vailing concentrations in 50/zl of human serum. Approximately 10/~g of Clq, 8 )< 1011 effec- 
tive molecules of C1, 7 X  109 effective molecules of oxidized C2, 20/~g of C4, and 70/~g of C3 
were used. When C1 and C4, or C1, C4, and C2 or C1, C4, C2, and C3 were employed, each 
component except for C1 was added to the V-Ab complex. C1 was then added and the mixture 
incubated in a vol of 0.25 ml at 37°C for 20 rain. The various samples of virus, V-Ab or V-Ab-C 
were then layered on 5-20%  (wt/vol) linear sucrose gradients (50 mM Tris, 0.15 M  sodium 
chloride, pH 8) which were formed over 0.3 ml of 65% sucrose. The gradients were centrifuged 
at 4°C at 114,000  g for 18 rain in a  50.1 rotor in a Beckman L2-65 ultracentrifuge (Beckman 
Instruments, Inc.). 
Radioactive Analysis.--After centrifugation, fractions were collected from gradient tubes 
and assayed  for radioactivity and  refractive index.  12~I samples were counted in a  Baird 
Atomic gamma well counter (Baird Atomic, Inc., Bedford, Mass.). In some experiments frac- 
tions were precipitated with 10% TCA in the presence of 0.1 mg BSA before counting. Frac- 
tions containing either 3H or 14C were collected directly into 15 ml of aquasol containing water 
(75 ml/liter) and glacial acetic acid (50 ml/liter). Alternatively, the fractions were treated with 
10% TCA and the precipitates collected on gs/A filters. The filters were washed three times 
with 5% TCA, dried under an infrared lamp, placed in a vial containing 8 ml of aquasol, and 
counted in a Beckman LS-230 spectrometer (Beckman Instruments, Inc.). 
Sizing of V-Ab and V-Ab-C Complexes.--Markers  used to size the V-Ab and V-Ab-C com- 
plexes  were  radiolabeled  polyoma  virus  (242S),  rabies  virus  (550S) 2 and  bacteriophages  s 
2 Rabies virus, HEP strain, was kindly supplied by T. Wiktor, Wistar Institute, Philadel- 
phia, Pa. 
8 The assays were kindly done by Dr. Junetsu Ito, Department of Microbiology, Scripps 
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q%15 (262S), and T7 (453S) (21, 22). The position of phages in the various gradients was con- 
firmed by plaquing gradient fractions on susceptible bacterial cultures.a 
Electron Microscope Studies.--Mixtures of virus,  V-Ab and V-Ab-C were resuspended in 
50X of distilled water and mixed immediately with 50X of 3070 phosphotungstic acid, pH 6. A 
drop of the mixture was placed on an electron microscope grid and excess fluid removed with 
absorbent paper; the grid was observed immediately in the electron microscope. 
Virus Neutralization Studies.--The antibody and C neutralization  test was done in vitro by 
use of standard  plaque assay techniques (23). In all instances, virus was first incubated with 
antibody for 5 rain at room temperature and then with C or C components for 30 min at 37°C 
with gentle agitation.  Control mixtures were incubated  with C buffer for the same period of 
time under similar conditions. 
RESULTS 
Effects  of Radioactive  Labeling on Polyoma Virus.--After surface labeling with 
iodine,  polyoma virus  sedimented  in cesium chloride equilibrium  density  gra- 
dients  as  a  single  sharp  peak with  its  characteristic  buoyant density  of  1.32 
g/ml  (Fig. 1 a)  (11). In sucrose density gradients,  labeled polyoma sedimented 
as a 242S peak of radioactivity (Fig. 2). Electron microscope studies showed no 
gross morphological changes in virus structure (Fig. 1 b). Over 95 % of the radio- 
activity was precipitable if labeled virus was first incubated with hamster anti- 
body to polyoma virus and then with rabbit antibody to hamster IgG. Polyoma 
virus was not precipitated  under  these  conditions  if first mixed with  hamster 
antibody to SV40 virus.  Although labeled  polyoma virus  appeared physically 
intact  as indicated  above, infectivity studies showed a  loss of from 1-5  X  102 
PFU/ml  after  labeling  with  iodine.  Loss  of  infectivity  was  not  reduced  by 
changes in the conditions employed for labeling or through use of lactoperoxi- 
dase. 
Effect  of Antibody on Polyoma Virus.--Mixtures of '25I-labeled polyoma virus 
and varying amounts of 131I-labeled  IgG fraction of hamster antipolyoma anti- 
body  were  analyzed  by  sucrose  gradient  ultracentrifugation.  As  depicted  in 
Fig. 3, increasing amounts of antibody shifted the sedimentation  rate of [12~I]- 
polyoma virus in increments,  and 131I-labeled  antibody cosedimented with  the 
virus. In comparison to markers sedimented in parallel with the V-Ab mixtures, 
the sedimentation  rate of polyoma virus was enhanced from 242S to 260S with 
the least  amount of antibody employed. We knew the specific radioactivity of 
the IgG fraction of antipolyoma virus antibody and thus were able to determine 
the number of molecules of antibody bound to polyoma virus from the number 
of 13~I counts cosedimenting with the virus. By comparison of these values with 
the number of polyoma virions (HAU titer of [n~I]virus) present in the reaction 
mixtures,  we were able to calculate that the 242S-260S sedimentation  rate en- 
hancement  was  accomplished  by  2  antibody  molecules/virion  (Table  I).  An 
Fro. 1. Panel a, cesium chloride equilibrium density gradient of 12SI-labeled  polyoma virus. 
The radioactive peak had a buoyant density of 1.32 g/ml and, as shown in the lower portion, 
was precipitable with antibody to polyoma virus. Panel b, electron microscope examination of 
125i_radiolabeled polyoma virus. 0 
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Fro. 2.  Sucrose gradient ultracentrifugal analysis of [aH]thymidine-labeled polyoma virus. 
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FIG. 3.  Sucrose gradient ultracentrifugal analyses of 12SI-labeled  polyoma virus incubated 
with varying amounts of  131I-labeled  antipolyoma antibody. In each panel a portion of the 
zzzI-labeled antibody cosedimented with the labeled polyoma virus. The sedimentation rates 
of the complexes by comparison with marker proteins were 260S, 350S and 410S for the experi- 
ments shown in  the  upper,  middle,  and  lower panels,  respectively.  Calculations  from  the 
amount of IgG cosedimenting with the virus and the specific radioactivity permitted a deter- 
mination of the number of antibody molecules per virus particle as shown in Table I. M.  B.  A.  OLDSTONE,  N.  R.  COOPER,  AND  D.  L.  LARSON  555 
TABLE I 
Formation and  Characterization of  Various V-Ab Complexes 
Gradient description 
Virus*  Antibody$ 
Molecules of specific  Ratio Ab/V  S rate § 
antibody bound 
/zg 
3.2  X  109  0.00  0  242 
3.2  X  109  0.53  7.0  X  109  2.18/1  260 
3.2  X  109  5.30  30.6  X  109  9.57/1  350 
3.2  X  109  53.00  70.4  X  109  20.2/1  410 
* Number of virus particles calculated from the known number of HAU (320 HAU of 125I 
placed in each gradient tube); 1 HAU is equivalent to l0 T  virus particles. HAU determined 
after iodination of virus. 
:~ Sp act of antibody used was 3.19 X 105 cpm/#g protein. 
§ S rate was determined by use of the following markers: polyoma virus, rabies virus, 
¢-15, and T7 bacteriophages. 
additional  10-fold increment in antibody increased the number of bound anti- 
body molecules per virion 5-fold, to 10,  and shifted the sedimentation rate to 
350S. A further doubling of the antibody molecules per virion and an increase in 
the S rate to 410S was accomplished by an additional  10-fold increase in anti- 
body. 
Electron  microscope  examination  confirmed  that  polyoma  virus  particles 
were  cross-linked  and  agglutinated  in  the  presence  of  antibody  (Fig.  4 a). 
Normal hamster IgG did not lead to aggregation of polyoma virus. Under higher 
power,  strands  or  "whiskers" measuring  the  reported  size  of IgG molecules 
(24,  25)  were seen protruding from the surface of viral particles  (Fig. 4 b). In 
experiments using  an antibody concentration  of 5.3  ~g,  approximately 10-13 
strands or whiskers were counted/virion, which was in good agreement with the 
estimation,  by radioactivity  measurement,  of  10  molecules/virion  (Table  I). 
There was no evidence of disruption or fragmentation of virus particles in any 
electron microscope field. 
In  other  studies  the  effect  of  antibody  on  polyoma virus  infectivity  was 
examined. Doses of antibody in the range of approximately 1-2 antibody mole- 
cules  bound/virion,  which  are  the  amounts  employed in  most of the  studies 
described below, did not lead to significant virus neutralization.  When  10-fold 
higher doses of antibody were used, polyoma virus was neutralized in the ab- 
sence of serum. 
Effect  of Serum  on  Polyoma  Virus-Antibody  Complexes.--Sucrose  gradient 
ultracentrifugation  studies  were performed on V-Ab mixtures incubated  with 
fresh serum. The amount of antiviral antibody in 0.53/~g of hamster IgG was 
chosen for these studies. As shown in Fig. 5, serum increased the sedimentation 
rate of the V-Ab complex from approximately 260S to about 450S. In this study 
viral nucleic  acid  had  been  labeled  with  [3H]thymidine;  entirely  comparable 556 M.  B.  A.  OLDSTONE, N.  R.  COOPER~ AND D.  L.  LARSON  557 
results  were  obtained  with  [l%I]polyoma  virus.  The  enhanced  cross-linking 
produced by fresh serum was heat labile,  because serum previously heated at 
56°C for 30 rain was unable to enhance the sedimentation of V-Ab complexes. 
C did not lead to disruption of the outer viral coat with release of viral nucleic 
acid as shown by the lack of ~H counts near the top of the gradient after treat- 
ment of 3H-labeled  polyoma virus with antibody and C (Fig. 5). This conclusion 
was further strengthened when ~H-labeled polyoma virus proved to be resistant 
to DNase. Electron microscopic examination of V-Ab-C mixtures also failed to 
show evidence of virus disruption.  In addition, no ultrastructural  lesions  cor- 
responding to those produced by C in membranes (26, 27) were seen. 
Residual activity of the various C components in serum after incubation with 
V-Ab complexes was determined. As shown in Table II, polyoma virus-antibody 
complexes efficiently activated C. Consumption of all C components measured, 
including the terminal reacting components C8 and C9, was observed. 
Role of C Components in the Polyoma  V-A b-C Complex.--To better understand 
the role of various C components in enhancing cross-linking of polyoma virus- 
antibody complexes, guinea pig serum deficient in C4 and rabbit serum deficient 
in C6 were incubated with radiolabeled virus and 0.53 ~g of antibody. Rabbit 
serum deficient in C6 increased the sedimentation rate of the V-Ab complexes 
as well as did normal rabbit, human, or guinea pig serum. In contrast, guinea 
pig serum deficient in C4 was devoid of enhancing activity. 
These studies  indicated that early reacting C  components were involved in 
cross-linking  of  polyoma  virus-antibody  complexes.  Reaction  mixtures  of 
labeled V-Ab and various C components were prepared and ultracentrifuged in 
sucrose gradients. As demonstrated in Fig. 6, Clq markedly enhanced aggluti- 
nation  of V-Ab complexes.  However,  identical  mixtures of labeled  virus  and 
antibody with C1 and C4 did not result in enhanced agglutination, and attempts 
with larger amounts of C1  and C4 were unsuccessful. As shown in Fig. 7, mix- 
tures of polyoma virus and antibody with C1,  C4,  C2,  and C3 also  led  to en- 
hancement of the sedimentation rate of polyoma virus.  In the absence of C2, 
the sedimentation rate was not enhanced over that observed in the presence of 
antibody alone, which indicated an essential  role for activated C3 in enhance- 
ment of viral aggregation. 
Role of C and C Components in Viral Neutralization.--Polyoma virus was first 
incubated with  an amount of antibody which did not produce neutralization, 
and then this mixture was incubated with various combinations of serum or C 
components. As depicted in Table III, both whole serum and serum deficient in 
C6 were able to neutralize polyoma virus-antibody mixtures, while serum defi- 
cient in C4 was unable to do so. In correlation with the sucrose gradient ultra- 
FIG. 4.  Electron microscope examination of polyoma virus incubated with 5.3 #g of the 
IgG fraction of antipolyoma antibody. Low power and high power views are shown. In the 
higher power, examination shows the existence of strands or "whiskers" protruding from the 
viral surface. These whiskers measure within the reported size of IgG molecules (24, 25). 558  POLYOMA  VIRUS-ANTIBODY-COMPLEMENT IMMUNE  COMPLEXES 
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FIG. 5.  Sucrose gradient ultracentrifugal analysis of mixtures  of [3H]thymidine-labeled 
polyoma virus incubated with antibody or with antibody and serum. There is no evidence of 
viral lysis on treatment of polyoma virus with antibody and complement.  The sedimentation 
rate of the polyoma virus-antibody-complement  aggregate is approximately  450S. 
TABLE II 
Consumption  of C Components on Addition of Antiviral Antibody and Serum to 
Isolated Polyoma  Virus* 
C component  Percent C component depleted 
C1  75 
C4  97 
C2  97 
C3  50 
C5  60 
C6, C7  >50 
C8  60 
C9  67 
* These percentages represent consumption  of C by virus and antibody as compared to 
samples from which virus and antibody were omitted. In the absence of antibody, average 
consumption of C by polyoma virus was: C1 (20%), C2 (36%), C3 (0%), C4 (55%), C5 (20%), 
C6, C7 (not determined), C8 (24%), and C9 (0%). 
centrifugal studies, Clq but not C1 or C1  and  C4; and C1, C4, C2, and  C3  but 
not C1, C4, and C3 were able to neutralize polyoma virus-antibody complexes. 
DISCUSSION 
The specific immunologic factors which function in the host's defense against 
pathogenic viruses may include antibody, antibody and C, sensitized lympho- 
cytes, and phagocytic elements. The  roles of each and  the mechanisms which 
facilitate neutralization  and  clearance  of  virus  on  one  hand  or permit  viral 
persistence on the other are incompletely understood. Antibody may neutralize 
a  virus  by  interfering  with  viral  attachment,  by  aggregating  viruses,  or  by 
stimulating engulfment by phagocytic elements. The protective role of antibody M.  B.  A.  OLDSTONE,  N.  R.  COOPER,  AND  D.  L.  LARSON  559 
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Fro. 7.  Sucrose gradient ultracentrifugal analysis of 12SI-labeled polyoma virus incubated 
with antibody and C1, C4, C2, and C3 or with C1, C4, and C3. Aggregation is dependent on 
activation of C3. 
has been amply demonstrated in epidemiologic surveys of man and experimental 
studies in animals, as well as by use of viral vaccines, and passive administration 
of antibody. In these instances the role of the C system which may be activated 
by V-Ab immune complexes must be considered. In addition to possibly mediat- 
ing viral lysis, the bound C proteins on the virion surface provide sites which 
may cause the complex to be handled differently in vivo. In particular, bound C 
components may enhance attachment of the V-Ab complex to phagocytic cells 
and to B lymphocytes. While this may facilitate virus destruction and perhaps 
formation of additional antibody, it may, with certain viruses, provide a means 560  POLYOMA  VIRUS-ANTIBODY-COMPLEMENT  IMMUNE  COMPLEXES 
TABLE III 
Role of Various C Components in Enhanced Neutralization of V-Ab Complex* 
Reagents added to virus-antibody mixture  % Virus neutralization 
Medium  0 
Heated guinea pig serum  0 
Normal guinea pig serum  86 
C4-deficient guinea pig serum  0 
Normal rabbit serum  73 
C6-deficient rabbit serum  65 
Normal human serum  80 
Purified C1  0 
Purified C1, C4  0 
Purified C1, C4, C2  0 
Purified C1, C4, C2, C3  84 
Purified Clq  60 
* For the polyoma plaque and neutralization  assay stock polyoma virus was diluted and 
mixed with a dilution of rabbit antibody  to polyoma virus to give 50-55 PFU on confluent 
mouse embryo monolayers per 60 )<  15 mm Falcon petri dish. All mixtures were diluted  in 
Eagle's basic medium and incubated at 37°C for 30 min; a final vol of 200)t was added  to mid 
log Ha/ICR embryo cells. 
for virus  entry  into  cells  and/or  furnish  an  environment  conducive  to virus 
persistence or replication. 
In the present study with polyoma virus, we have found that antibody may 
physically agglutinate virus particles and that this process was associated with 
the  ability  of antibody  to  neutralize  polyoma virus  infectivity.  Further,  the 
formation of V-Ab aggregates and the accompanying virus neutralization  were 
significantly enhanced by C. Very limited  amounts of antibody,  only 2 mole- 
cules of antibody bound/virion, were able to activate C and so cause formation 
of large viral aggregates.  In rate zonal centrifugation  studies with mixtures of 
polyoma virus  whose nucleic acid has  been  labeled  with  [3H]thymidine,  anti- 
body, and C showed enhanced virus  aggregation with radioactive counts being 
both restricted  to the V-Ab-C complex location and resistant  to  DNase treat- 
ment. If viral lysis had occurred, radiolabeled nucleic acid would have appeared 
at the top of the gradient and [3H]thymidine counts would have been degraded 
by DNase. The lack of viral lysis by antibody and C was further supported by 
electron microscope analyses. 
These studies  clearly demonstrate  that C, in the presence of small amounts 
of antibody, enhances virus aggregation. This process has the effect of greatly 
reducing the net number of infectious particles and probably explains the aug- 
mented neutralization of infectivity observed in such mixtures. This is the first 
experimental  verification  of this  C-dependent  mechanism of virus  neutraliza- 
tion. Although Wallis and Melnick earlier postulated  C-associated aggregation 
as  the  mechanism  for  the  neutralization  of Herpes  simplex  virus  (28),  sub- M.  B.  A.  OLDSTONE,  N.  R.  COOPER,  AND  D.  L.  LARSON  561 
sequent data of Daniels and his associates (29) using C1 and C4 to enhance the 
neutralization of Herpes simplex virus-antibody complex indicated that C acts 
by contributing bulk  to  the  viral  surface or  by some  other mechanism  not 
dependent on C3. Bound C4 or C3 were able to facilitate neutralization if large 
amounts were used. Further, using radiolabeled Herpes simplex virus, Notkins 
and his colleagues (30, 31) were unable to show any enhanced aggregation of the 
V-Ab  complex with the addition of complement. Linscott et al. postulated a 
bulk-producing role for C in Newcastle disease virus neutralization, which re- 
quired  the  first  four C  components  (32).  Finally,  Berry  and  Almeida  (33), 
using electron microscopy, noted that addition of antibody to avian bronchitis 
virus caused formation of large aggregates of virus particles and a 300°~- halo 
around the virus. After addition of fresh serum to the virus-antibody mixture, 
no increase in virus antibody aggregation was noted, although the halo of bound 
protein  more  than  doubled  in  diameter.  Thus,  this  study  also  suggested  C 
enhancement of neutralization by protein blanketing of the virion. 
Another  mechanism  of  C  enhancement  of viral  neutralization  is  through 
disruption of the viral envelope or viral lysis. C-mediated viral lysis has been 
demonstrated with Gross leukemia (AKR) virus (34), Moloney leukemia virus 
(2), and equine arteritis virus (35)  by use of sucrose gradient ultracentrifuga- 
tion  analysis  of  internally  labeled  virus  reacted  with  antibody  and  C.  Our 
electron microscope examination of Moloney leukemia virus reacted with anti- 
body and  C  revealed marked distortion of viral  architecture with  a  twofold 
increase  in  diameter,  decreased radio-opacity, and  presence of typical  C-de- 
pendent ultrastructural lesions.  ~ Similar ultrastructural  lesions after C  action 
have been shown on avian bronchitis, influenza, and rubella viruses (25). 
Our studies indicate that Clq is able to aggregate virus with accompanying 
neutralization.  Since Clq does not occur free in the circulation, it is unlikely 
that aggregation by Clq is biologically important. Native C1, which is a com- 
plex of Clq with Clr and Cls,  did not possess this aggregating ability, in all 
probability because some Ig-binding sites on Clq are masked or rendered un- 
reactive in the presence of Clr and Cls. Agglutination did not occur with se- 
quential addition of C1 and C4, even in excess, or with C1, C4, and C2; how- 
ever, enhanced aggregation and neutralization were evident on addition of C3 
and  C1,  C4  and C2  to  the  V-Ab  complex.  This  finding  documents  an 
essential role  for  C3  in  facilitating  cross-linking  of polyoma virus-antibody 
complexes. Preliminary evidence indicates that polyoma virus possesses a  re- 
ceptor for C3b which binds C3b deposited on surfaces during activation of the C 
system. ~ 
The complexes formed with isolated C1, C4, C2, and C3  added to polyoma 
virus-antibody complexes were somewhat larger than those generated by addi- 
tion of whole serum. While the reason for this is not clear, it is possible that C3 
4 Cooper, N. R., M. J. Polley,  and M. B. A. Oldstone. Manuscript in preparation. 
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inactivator  present  in  normal  serum  degrades  some bound  C3b  and  thereby 
reduces  the  number of cross-links and  the  aggregate size.  Other  possible ex- 
planations are that the quantitative relationships of C1, C4, C2, and C3 present 
in  serum  may  differ  from  those  of  the  isolated  components  or  other  serum 
inhibitors,  such as C1  inhibitor,  may influence C  activation. These conditions 
might well lead to reduced C3b binding. 
The binding  of C1,  4,  2,  3  to  the V-Ab complex has important  theoretical 
implications.  Macrophages, monocytes, polymorphonuclear leukocytes, and B 
lymphocytes have receptors for C3b and these cells bind complexes bearing C3. 
This binding may be followed by phagocytosis of the V-Ab-C1, 4, 2, 3 complex. 
Monocytes and  fixed phagocytes of  the  reticuloendothelial  system may con- 
centrate and handle V-Ab-C mixture in this way, while attachment to B lym- 
phocytes may facilitate infection of this cell type. This mechanism may explain 
why  cells  with  C3  receptors,  i.e.  B  lymphocytes  (36-38)  and  macrophages 
(39-42),  usually  carry virus during persistent  infections.  In  studies  to be re- 
ported  later,  6 the  importance of C3  in  the  clearance  of V-Ab complexes was 
shown by delayed removal of polyoma virus-antibody complexes from the serum 
after in vivo depletion of C3 by cobra factor treatment. 
SUMMARY 
Interaction of polyoma virus,  specific antibody,  and  complement has been 
studied.  Firm  evidence  has  been  gathered  that  C1  through  C3  and  not  C5 
through  C9  enhance  neutralization  of virus-antiviral  antibody  (V-Ab)  com- 
plexes.  C  enhancement of neutralization  occurs primarily by agglutination  of 
V-Ab complexes and not by virion lysis or attachment of large protein mole- 
cules to the V-Ab complex. In this model, binding of C1, 4,  2, 3  to the V-Ab 
complex may explain  why some viruses concentrate  in  or infect certain  cells 
bearing C3 receptors such as B lymphocytes, macrophages, and monocytes. 
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